Enlivex Therapeutics (NASDAQ: ENLV) schedules Extraordinary General Meeting in Israel

Rhea-AI Filing Summary

Enlivex Therapeutics Ltd. reported that it has scheduled an Extraordinary General Meeting of Shareholders. The meeting will take place on February 3, 2026, at 7:00 p.m. Israel time at the company’s offices at 14 Einstein Street, Nes Ziona, Israel.

The company has prepared a notice, proxy statement and proxy card for this meeting, which are included as exhibits to this report and incorporated by reference into several existing registration statements on Forms S-8 and F-3. Shareholders can use the proxy materials to review the matters to be voted on and to submit their voting instructions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 12/18/2025 - 04:30 PM Learn about SEC filing dates

FAQ

What did Enlivex Therapeutics Ltd. (ENLV) disclose in this Form 6-K?

Enlivex Therapeutics Ltd. disclosed that it will hold an Extraordinary General Meeting of Shareholders and attached the related notice, proxy statement and proxy card as exhibits.

When and where is Enlivex (ENLV) holding its Extraordinary General Meeting of Shareholders?

The Extraordinary General Meeting of Shareholders is scheduled for February 3, 2026, at 7:00 p.m. Israel time, at Enlivex’s offices at 14 Einstein Street, Nes Ziona, Israel 7403618.

What documents related to the Enlivex (ENLV) shareholder meeting are included with this report?

The report includes as exhibits a Notice and Proxy Statement for the Extraordinary General Meeting (Exhibit 99.1) and a Form of Proxy Card (Exhibit 99.2).

How are the Enlivex (ENLV) meeting materials used in the company’s existing SEC registrations?

The information in this report, including Exhibits 99.1 and 99.2, is incorporated by reference into Enlivex’s registration statements on Forms S-8, F-3 and F-3MEF identified by several file numbers.

Who signed the Enlivex (ENLV) Form 6-K regarding the Extraordinary General Meeting?

The report was signed on behalf of Enlivex Therapeutics Ltd. by Oren Hershkovitz, who is identified as the company’s Chief Executive Officer.

Where can Enlivex (ENLV) shareholders find details of the matters to be voted on at the meeting?

Details of the matters to be voted on are contained in the Notice and Proxy Statement attached as Exhibit 99.1 to the report.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: December 2025

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

Extraordinary General Meeting of Shareholders

On December 18, 2025, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), announced that it will hold an Extraordinary General Meeting of Shareholders of the Company (the “Meeting”) on Tuesday, February 3, 2026, beginning at 7:00 p.m. Israel time, at the offices of the Company located at 14 Einstein Street, Nes Ziona, Israel 7403618. Copies of the notice and proxy statement and the related proxy card are attached to this Report on Form 6-K as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference. 

The information contained in this Current Report on Form 6-K, including Exhibits 99.1 and 99.2, is hereby incorporated by reference into the Company’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926 and File No. 333-286956), filed with the SEC. 

Exhibit No.
99.1		Enlivex Therapeutics Ltd. Notice and Proxy Statement for the Extraordinary General Meeting of Shareholders to be held on February 3, 2026.
99.2		Form of Proxy Card.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Enlivex Therapeutics Ltd.
	(Registrant)
	By:	/s/ Oren Hershkovitz
	Name:  Title:	Oren Hershkovitz Chief Executive Officer

Date: December 18, 2025

 2